<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3512436</article-id><article-id pub-id-type="publisher-id">18091</article-id><article-id pub-id-type="doi">10.7448/IAS.15.6.18091</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Abstract &#x02013; P8</subject></subj-group></article-categories><title-group><article-title>Does a simplified regimen give a better adherence, treatment satisfaction, and quality of life?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Langebeek</surname><given-names>N</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Sprengers</surname><given-names>H</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Gisolf</surname><given-names>E</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Richter</surname><given-names>C</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Sprangers</surname><given-names>M</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Reiss</surname><given-names>P</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Nieuwkerk</surname><given-names>P</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Rijnstate Hospital, Department of Internal and Infectious Diseases, Arnhem, Netherlands</aff><aff id="AF0002"><label>2</label>University Medical Center, Groningen, Netherlands</aff><aff id="AF0003"><label>3</label>Academic Medical Center, Amsterdam, Netherlands</aff><pub-date pub-type="epub"><day>11</day><month>11</month><year>2012</year></pub-date><pub-date pub-type="collection"><year>2012</year></pub-date><volume>15</volume><issue>Suppl 4</issue><elocation-id content-type="doi">18091</elocation-id><permissions><copyright-statement>&#x000a9; 2012 Langebeek N et al.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background</title><p>Adherence to treatment is the key to the success of combination antiretroviral therapy (cART) for HIV infection. It is generally assumed that simplification of cART will lead to better adherence, higher treatment satisfaction, and quality of life (QoL), but randomized studies demonstrating such advantages of simplified regimens are scarce.</p></sec><sec id="st2"><title>Methods</title><p>Antiretroviral-na&#x000ef;ve patients who achieved viral load &#x0003c;50 c/ml in two consecutive samples between 12&#x02013;24 weeks after commencing induction therapy with bid lopinavir/ritonavir (LPV/r) and fixed-dose combination AZT/3TC (Combivir<sup>&#x000ae;</sup>) were randomly assigned to either continue LPV/r/Combivir<sup>&#x000ae;</sup> or switch to simplified therapy with bid fixed-dose AZT/3TC/abacavir (Trizivir<sup>&#x000ae;</sup>). Both arms yielded similar antiviral efficacy after 48 weeks as reported previously [1]. Patients completed standardized questionnaires on adherence (Simplified Medication Adherence Questionnaire (SMAQ)), treatment satisfaction (HIVTSQ) and QoL (MOS-HIV) at randomization and at weeks 48, 72 and 96. Adherence data were analyzed using generalized estimating equations, and satisfaction and QoL using mixed linear models.</p></sec><sec id="st3"><title>Results</title><p>Patients in the Trizivir<sup>&#x000ae;</sup>-group (n=30) tended to skip fewer doses both during the preceding 7 days (p=0.055) and during the preceding weekend (p=0.09) than patients in the LPV/r-group (n=20). Moreover, patients in the Trizivir<sup>&#x000ae;</sup>-group found their regimen significantly more convenient (p=0.022) than patients in the LPV/r-group. However, patients in the LPV/r-group reported a better QoL than patients in the Trizivir<sup>&#x000ae;</sup>-group in the domains measuring cognitive functioning (p=0.003), energy/fatigue (p=0.046) and social functioning (p=0.074).</p></sec><sec id="st4"><title>Conclusions</title><p>In this randomized trial simplification of therapy to fixed-dose Trizivir<sup>&#x000ae;</sup> was perceived to be more convenient, and tended to result in improved adherence, but at the expense of a lower level of QoL. Our findings suggest that the choice for simplified regimens should be individualized and may involve a trade-off between convenience and QoL.</p></sec></abstract></article-meta></front><back><ref-list><title>Reference</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprenger</surname><given-names>HG</given-names></name><name><surname>Langebeek</surname><given-names>N</given-names></name><name><surname>Mulder</surname><given-names>PG</given-names></name><name><surname>Ten</surname><given-names>Napel CH</given-names></name><name><surname>Vriesendorp</surname><given-names>R</given-names></name><name><surname>Hoepelman</surname><given-names>AI</given-names></name><etal/></person-group><article-title>Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-na&#x000ef;ve patients: FREE randomized trial interim results</article-title><source>AIDS Patient Care STDs</source><year>2010</year><volume>24</volume><fpage>361</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20515418</pub-id></element-citation></ref></ref-list></back></article>